Diana Shuster has been a clinical pharmacologist for more than 9 years, working for large and small pharma companies, as well as a CRO. At Recursion, Diana is the clinical pharmacology lead for multiple rare disease and oncology compounds in clinical development. Before joining Recursion, Diana spent 4.5 years at PRA Health Sciences supporting the award of 40+ clinical studies focused in Phase 1 clinical development (FIH, renal impairment, human ADME and DDI studies). While there, Diana served as a strategic partner, leading and creating clinical pharmacology development plans and pediatric development plans for multiple compounds in cardiovascular disease, fibrosis and virology. Prior to that, Diana worked at AbbVie for 2 years supporting the global clinical pharmacology development plan for Viekira Pak™, including label expansion studies in end-stage renal disease, organ transplant patients, adolescents with Hepatitis C infection, and healthy Chinese, South Korean or Taiwanese participants. Diana also worked at Seattle Genetics for almost 2 years supporting preclinical characterization of Adcetris™ pharmacokinetics. Diana earned her PhD from the University of Washington. She is a group fitness instructor and enjoys spending time with her young family.